ADMA Biologics Inc (ADMA)

Debt-to-equity ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	72,337	101,326	131,074	130,847	130,594	142,026	140,312	144,301	142,833	141,366	139,811	138,423	94,866	94,363	93,877	93,413	92,969	97,044	96,574	96,129
Total stockholders’ equity	US$ in thousands	349,018	231,890	188,269	153,706	135,206	151,437	146,762	145,655	151,974	100,385	114,401	126,933	141,173	102,780	111,594	112,504	88,249	71,376	76,879	96,336
Debt-to-equity ratio		0.21	0.44	0.70	0.85	0.97	0.94	0.96	0.99	0.94	1.41	1.22	1.09	0.67	0.92	0.84	0.83	1.05	1.36	1.26	1.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $72,337K ÷ $349,018K
= 0.21

The debt-to-equity ratio of ADMA Biologics Inc has fluctuated over the past few years, indicating changes in its capital structure and financial leverage.

Between March 2020 and September 2021, the debt-to-equity ratio generally increased from 1.00 to 0.92, reaching a peak of 1.41 in September 2022. This upward trend suggests that the company was relying more on debt financing relative to equity during this period.

However, from December 2021 to December 2024, the debt-to-equity ratio gradually decreased from 0.67 to 0.21. This downward trend indicates that ADMA Biologics Inc has been reducing its reliance on debt and strengthening its equity position over time.

Overall, a decreasing debt-to-equity ratio typically indicates lower financial risk and a more stable capital structure. It appears that ADMA Biologics Inc has been proactive in managing its debt levels and improving its financial health in recent years.